PRECISION BIOSCIENCES INC — Form 8-K
Filed August 24, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Precision BioSciences announced first patient dosing in August 2026 in the Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD, an in vivo gene-editing therapy for Duchenne muscular dystrophy. The trial targets ambulatory DMD patients aged 2–7 with exons 45–55 mutations (affecting ~60% of DMD patients); first site was Arkansas Children's Hospital. Initial safety data expected by year-end 2026. No financial figures, partnership amounts, or share issuances disclosed in this filing.
Why this rating
Phase 1/2 dosing milestone is material for a $47.1M clinical-stage biotech; first-in-human data in rare orphan indication with FDA Fast Track and PRV eligibility represents meaningful clinical/regulatory progress, but outcome remains uncertain.
Tradability signal
NO TRADE
No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.13% over 4 hrs, n=14).
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · backfill $9.01 | +10 min · backfill $8.82 ▼ 2.11% | +30 min · backfill $9.27 ▲ 2.89% | +1 hr · backfill $8.80 ▼ 2.33% | +4 hrs · backfill $8.63 ▼ 4.22% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.